BioSpace News Archive

Immunovia’s bloodtest IMMray™ PanCan-d was mentioned in the seminar “The latest in early detection for pancreatic cancer” arranged by Pancreatic Cancer Action Network (pancan.org) on April 15, 2021.

Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today announced that results from the US Phase 3

Deep Lens and Oregon Oncology Specialists today announced a strategic collaboration that will integrate Deep Lens’ artificial-intelligence (AI)-based clinical trial screening platform, VIPER™, into their community oncology practice network. VIPER uses proprietary cloud-based technology to facilitate, triage and accelerate the clinical trial recruitment process.

Alkame Holdings, Inc. (OTC PINK:ALKM), is pleased to provide an update to our valued shareholders. As our company forges ahead in todays COVID-19 marketplace we are constantly adapting and evolving for long term success.

Merger enables an increased focus on product innovation, more cutting-edge regenerative medicine research and strategic collaborations with other complementary technology companies.

10 accepted abstracts include five oral presentations from pioneering artificial intelligence (AI) collaboration Presentations support the potential of intravitreal pegcetacoplan, an investigational targeted C3 therapy, as the first treatment for geographic atrophy (GA)

The Government of Canada is working with all partners to protect the health and safety of Canadians and to reduce the spread of COVID-19 and the variants of concern in Canada.

Seigla Medical, Inc., announced conformité européenne (CE) Mark for the company’s LiquID™ Guide Catheter Extension for use in coronary and peripheral vasculature interventions. Guide catheter extensions are a crucial tool used by cardiologists worldwide to assist in the delivery of stents and other interventional devices.

Afya Limited, or Afya (Nasdaq: AFYA) today announced the acquisition of 100% of the total share capital of Cliquefarma, a healthtech company operating a free-to-use website that tracks prescription drugs, cosmetics and personal hygiene product prices in Brazil

Gyroscope Therapeutics, a clinical-stage gene therapy company focused on treating diseases of the eye, today announced it has filed a registration statement on Form F-1 (the “Registration Statement”) with the U.S. Securities and Exchange Commission (the “SEC”) relating to a proposed initial public offering (“IPO”) in the United States of its American Depositary Shares (“ADSs”), each representing one ordinary share.